Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Updates to the list of specialty drugs that will require precertification

December 21, 2017

Effective January 1, 2018, Independence will make the changes detailed below to specialty drugs requiring precertification under the medical benefit.

Additions

New precertification requirements will apply to Independence commercial and Medicare Advantage HMO and PPO members for the following specialty drugs as of January 1, 2018:

  • Fasenra? (benralizumab)
  • Luxturna? (voretigene neparvovec)
  • Mvasi? (bevacizumab-awwb)
  • Radicava? (edaravone)
  • Somatuline? Depot (lanreotide)
  • Sustol? (granisetron extended release)

In addition, the following drugs are currently pending approval from the U.S. Food and Drug Administration (FDA). These drugs will require precertification from Independence once they receive FDA approval in 2018, or on January 1, 2018, for any drug approved in 2017:

  • Exenatide sustained-release ITCA 650
  • Herceptin? (trastuzumab) biosimilar
  • Neulasta? (pegfilgrastim) biosimilar
  • Rituxan? (rituximab) biosimilar

Deletions

The following drugs will no longer require precertification from Independence as of January 1, 2018:

  • Berinert? (C1 esterase inhibitor [human])*
  • Cinryze? (C1 esterase inhibitor [human])*
  • Cubicin? (daptomycin)
  • Faslodex? (fulvestrant)
  • Kalbitor? (ecallantide)
  • Myozyme? (alglucosidase alfa)
  • Ruconest? (C1 esterase inhibitor recombinant)*
  • Synribo? (omacetaxine mepesuccinate)

These changes are reflected in an updated precertification requirement list, which has been posted to our website.

Please note: In a previously published version of this article, Independence stated that the drugs Emend? for injection (fosaprepitant), Cinvanti? (aprepitant), and Varubi? (rolapitant) would require precertification approval effective January 1, 2018. Based on provider feedback, Independence has reconsidered this position. Therefore, these three drugs will not require precertification approval.

*Effective January 1, 2018, these drugs will no longer be eligible for coverage under the medical benefit. As self-administered drugs, they will now be eligible for coverage under the pharmacy benefit for members with Independence prescription drug coverage. Members who do not have prescription drug coverage through Independence should contact their pharmacy benefits manager to determine if coverage for these self-administered drugs is available.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.